Chemocentryx Company Profile
✉ Email this page to a colleague
What is the competitive landscape for CHEMOCENTRYX, and when can generic versions of CHEMOCENTRYX drugs launch?
CHEMOCENTRYX has one approved drug.
There are three US patents protecting CHEMOCENTRYX drugs.
There are sixty-six patent family members on CHEMOCENTRYX drugs in thirty-five countries and ten supplementary protection certificates in ten countries.
Drugs and US Patents for Chemocentryx
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Chemocentryx | TAVNEOS | avacopan | CAPSULE;ORAL | 214487-001 | Oct 7, 2021 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | |||||
Chemocentryx | TAVNEOS | avacopan | CAPSULE;ORAL | 214487-001 | Oct 7, 2021 | RX | Yes | Yes | 8,906,938 | ⤷ Try a Trial | Y | Y | ⤷ Try a Trial | ||
Chemocentryx | TAVNEOS | avacopan | CAPSULE;ORAL | 214487-001 | Oct 7, 2021 | RX | Yes | Yes | 8,445,515 | ⤷ Try a Trial | Y | Y | ⤷ Try a Trial | ||
Chemocentryx | TAVNEOS | avacopan | CAPSULE;ORAL | 214487-001 | Oct 7, 2021 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | |||||
Chemocentryx | TAVNEOS | avacopan | CAPSULE;ORAL | 214487-001 | Oct 7, 2021 | RX | Yes | Yes | 11,603,356 | ⤷ Try a Trial | Y | Y | ⤷ Try a Trial | ||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for Chemocentryx Drugs
Country | Patent Number | Estimated Expiration |
---|---|---|
Slovenia | 2381778 | ⤷ Try a Trial |
Colombia | 6400172 | ⤷ Try a Trial |
Japan | 2012513402 | ⤷ Try a Trial |
Mexico | 2011006550 | ⤷ Try a Trial |
Croatia | P20171176 | ⤷ Try a Trial |
Brazil | PI0923384 | ⤷ Try a Trial |
>Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Chemocentryx Drugs
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
2381778 | 122022000029 | Germany | ⤷ Try a Trial | PRODUCT NAME: AVACOPAN; REGISTRATION NO/DATE: EU/1/21/1605 20220111 |
2381778 | C202230016 | Spain | ⤷ Try a Trial | PRODUCT NAME: AVACOPAN Y SALES FARMACEUTICAMENTE ACEPTABLES DEL MISMO; NATIONAL AUTHORISATION NUMBER: EU/1/21/1605; DATE OF AUTHORISATION: 20220111; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/21/1605; DATE OF FIRST AUTHORISATION IN EEA: 20220111 |
2381778 | 17/2022 | Austria | ⤷ Try a Trial | PRODUCT NAME: AVACOPAN, GEGEBENENFALLS IN FORM EINES PHARMAZEUTISCH ANNEHMBAREN SALZES; REGISTRATION NO/DATE: EU/1/21/1605 (MITTEILUNG) 20220119 |
2381778 | LUC00258 | Luxembourg | ⤷ Try a Trial | PRODUCT NAME: AVACOPAN ET LES SELS PHARMACEUTIQUEMENT ACCEPTABLES QUI EN DERIVENT; AUTHORISATION NUMBER AND DATE: EU/1/21/1605 20220119 |
3508477 | PA2022006 | Lithuania | ⤷ Try a Trial | PRODUCT NAME: AVAKOPANAS IR JO FARMACINIU POZIURIU PRIIMTINOS DRUSKOS ; REGISTRATION NO/DATE: EU/1/21/1605 20220111 |
2381778 | 2022C/518 | Belgium | ⤷ Try a Trial | PRODUCT NAME: TAVNEOS - AVACOPAN ET SES SELS PHARMACEUTIQUEMENT ACCEPTABLES; AUTHORISATION NUMBER AND DATE: EU/1/21/1605 20220119 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Here is a list of applicants with similar names.